Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
16 hedge funds and large institutions have $15.6M invested in Calliditas Therapeutics AB American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
6% less funds holding
Funds holding: 17 → 16 (-1)
7% less capital invested
Capital invested by funds: $16.7M → $15.6M (-$1.09M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$62.1K |
| 2 |
Optiver Holding
Amsterdam,
Netherlands
|
+$9.69K |
| 3 |
Jane Street
New York
|
+$1.08K |
| 4 |
JP Morgan Chase
New York
|
+$366 |
| 5 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$518K |
| 2 |
CG
Cutler Group
San Francisco,
California
|
-$25.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$14.9K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$12K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$10.3K |
CALT Hedge Fund Activity: Q2 2022 in Review
16 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q2 2022, worth a combined $15.6M — down 6.5% from $16.7M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CALT and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Morgan Stanley, adding an estimated $62.1K. The largest seller was Marshall Wace, exiting entirely with an estimated $518K sold.
- 16 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q2 2022, down from 17 in Q1 2022.
- Funds reported $15.6M of Calliditas Therapeutics AB American Depositary Shares stock for Q2 2022, down 6.5% quarter-over-quarter.
- 1 fund opened new Calliditas Therapeutics AB American Depositary Shares positions in Q2 2022 and 2 closed out, a net change of -1 holder.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q2 2022 was Morgan Stanley, an estimated $62.1K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q2 2022 was Marshall Wace, an estimated $518K sold.
Based on aggregated 13F filings for Q2 2022.